Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Chen, Liqun ^a   Bourguignon, Lilly Y W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; MICRORNA 21; PROTEIN BCL 2; PROTEIN C JUN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ADULT; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL NUCLEUS; CHEMOSENSITIVITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MIDDLE AGED; MOLECULAR INTERACTION; PROMOTER REGION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

INTRACISTERNAL A-PARTICLES;

ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONIC ACID; IMMUNOBLOTTING; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84897516001     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-52     Document Type: Article

References (60)

1. Toole BP, Hascall VC. Hyaluronan and tumor growth. Am J Pathol 2002, 161:745-747. 10.1016/S0002-9440(10)64232-0, 1867242, 12213700.
2. Bourguignon LY. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia 2001, 6:287-297. 10.1023/A:1011371523994, 11547898.
3. Bourguignon LY. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Sem. Cancer Biol. 2008, 18:251-259.
4. Toole BP, Wight TN, Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 2002, 277:4593-4596. 10.1074/jbc.R100039200, 11717318.
5. Auvinen PK, Parkkinen JJ, Johansson RT, Agren UM, Tammi RH, Eskelinen MJ, Kosma VM. Expression of hyaluronan in begnign and malignant breast lesion. Int J Cancer 1997, 74:477-481. 10.1002/(SICI)1097-0215(19971021)74:5<477::AID-IJC1>3.0.CO;2-0, 9355968.
6. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM. Hyaluronan in peritumoral stroma and maligmnant cells associated with breast cancer spreading and predicts survival. Am J Pathol 2000, 156:529-536. 10.1016/S0002-9440(10)64757-8, 1850058, 10666382.
7. Karihtala P, Soini Y, Auvinen P, Tammi R, Tammi M, Kosma VM. Hyaluronan in breast cancer: correlations with nitric oxide synthases and tyrosine nitrosylation. J Histochem Cytochem 2007, 55:1191-1198. 10.1369/jhc.7A7270.2007, 17827165.
8. Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci 1998, 111:1685-1694.
9. Wang C, Thor AD, Moore DH, Zhao Y, Kerschmann R, Stern R, Watson PH, Turley EA. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 1998, 4:567-576.
10. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002, 277:4589-4592. 10.1074/jbc.R100038200, 11717317.
11. Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, Cardiff RD. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1998, 176:206-215. 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3, 9618160.
12. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 1999, 43:269-287. 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5, 10423269.
13. Bourguignon LY, Singleton PA, Zhu H, Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 2003, 278:29420-29434. 10.1074/jbc.M301885200, 12748184.
14. Iida N, Bourguignon LY. Coexpression of CD44 variant (v10/ex14) and CD44S in human mammary epithelial cells promotes tumorigenesis. J Cell Physiol 1997, 171:152-160. 10.1002/(SICI)1097-4652(199705)171:2<152::AID-JCP5>3.0.CO;2-N, 9130462.
15. Ip YT, Davis RJ. Signal transduction by the c-JUN N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol 1998, 2:205-219.
16. Vlahopoulos S, Zoumpourlis VC. JNK: a key modulator of intracellular signaling. Biochemistry (Mosc) 2004, 69:844-854.
17. Angel P, Imagawa M, Chiu RJ, Stein B, Inmbra RJ, Rahmsdorf HJ, Jonat C, Herrlich P, Karin M. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 1987, 49:729-739. 10.1016/0092-8674(87)90611-8, 3034432.
18. Ritke MK, Bergoltz VV, Allan WP, Yalowich JC. Increased c-JUN/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem Pharmacol 1994, 48:525-533.
19. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 1999, 18:6063-6070. 10.1038/sj.onc.1202989, 10557095.
20. Abdul A, Zada P, Singh SM, Reddy VA, Elsässer A, Meisel A, Haferlach T, Tenen DG, Hiddemann W, Behre G. Downregulation of c-JUN expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation. Oncogene 2003, 22:2296-2308. 10.1038/sj.onc.1206393, 12700665.
21. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
22. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20. 10.1016/j.cell.2004.12.035, 15652477.
23. Ma F, Liu X, Li D, Wang P, Li N, Lu L, Cao X. MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolin-mediated IL-10 mRNA degradation. J Immunol 2010, 184:6053-6059. 10.4049/jimmunol.0902308, 20410487.
24. Dong J, Zhao YP, Zhou L, Zhang TP, Chen G. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res 2011, 42:8-14. 10.1016/j.arcmed.2011.01.006, 21376256.
25. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 2009, 284:26533-26546. 10.1074/jbc.M109.027466, 2785342, 19633292.
26. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce CM. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A 2006, 103:5078-5083. 10.1073/pnas.0600587103, 1458797, 16549775.
27. Song B, Wang C, Liu J, Wang X, Lv L, Wei L, Xie L, Zheng Y, Song X. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 2010, 29:29. 10.1186/1756-9966-29-29, 2853500, 20346171.
28. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008, 27:4373-4379. 10.1038/onc.2008.72, 18372920.
29. Bourguignon LY, Earle C, Wong G, Spevak CC, Krueger K. Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 2012, 31:149-160. 10.1038/onc.2011.222, 3179812, 21685938.
30. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008, 283:17635-17651. 10.1074/jbc.M800109200, 2427357,2427357, 18441325.
31. Bourguignon LY, Wong G, Earle C, Krueger K, Spevak CC. Hyaluronan-CD44 interaction promotes c-Src-mediated Twist signaling, microRNA-10b expression and RhoA/RhoC upregulation leading to Rho-Kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 2010, 285:36721-36735. 10.1074/jbc.M110.162305, 2978601, 20843787.
32. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009, 119:1518-1530. 10.1002/lary.20506, 2718060, 19507218.
33. Wang S, Bourguignon LY. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol 2011, 178:956-963. 10.1016/j.ajpath.2010.11.077, 3069910, 21356346.
34. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, Lisanti MP, Pestell RG. c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 2010, 285:8218-8226. 10.1074/jbc.M110.100792, 2832973, 20053993.
35. Wang J, Kuiatse I, Lee AV, Pan J, Giuliano A, Cui X. Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer Res 2010, 8:266-277. 10.1158/1541-7786.MCR-09-0221, 2824784, 20145041.
36. Franklin CC, Sanchez V, Wagner F, Woodgett JR, Kraft AS. Phorbol ester-induced amino terminal phosphorylation of c-Jun but not JunB regulates transcriptional activation. Proc Natl Acad Sci U S A 1992, 89:7247-7251. 10.1073/pnas.89.15.7247, 49683, 1496019.
37. Yu C, Minemoto Y, Zhang J, Liu J, Tang F, Bui TN, Xiang J, Lin A. JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 2004, 13:329-340. 10.1016/S1097-2765(04)00028-0, 14967141.
38. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012, 287:32800-32824. 10.1074/jbc.M111.308528, 3463333, 22847005.
39. Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K, Iba H. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol 2008, 378:492-504. 10.1016/j.jmb.2008.03.015, 18384814.
40. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261. 10.1073/pnas.0510565103, 1413718, 16461460.
41. Hunter AM. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007, 12:1543-1568. 10.1007/s10495-007-0087-3, 17573556.
42. Delpech B, Chevallier B, Reinhardt N, Julien JP, Duval C, Maingonnat C, Bastit P, Asselain B. Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int J Cancer 1990, 46:388-390. 10.1002/ijc.2910460309, 2394505.
43. Itano N, Kimata K. Expression cloning and molecular characterization of HAS protein, a eukaryotic hyaluronan synthase. J Biol Chem 1996, 271:9875-9878. 10.1074/jbc.271.17.9875, 8626618.
44. Weigel PH, Hascall VC, Tammi M. Hyaluronan synthases. J Biol Chem 1997, 272:13997-14000. 10.1074/jbc.272.22.13997, 9206724.
45. Spicer AP, Nguyen TK. Mammalian hyaluronan synthases: investigation of functional relationships in vivo. Biochem Soc Trans 1999, 27:109-115.
46. Stern R, Jedrzejas MJ. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 2006, 106:818-839. 10.1021/cr050247k, 2547145, 16522010.
47. Banerji S, Wright AJ, Noble M, Mahoney DJ, Campbell ID, Day AJ, Jackson DG. Structures of the CD44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nat Struct Mol Biol 2007, 14:234-239. 10.1038/nsmb1201, 17293874.
48. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA coding the lymphocyte homing receptor CD44 reveals 12 alternatively spliced exons. Proc Natl Acad Sci U S A 1992, 89:12160-12164. 10.1073/pnas.89.24.12160, 50718, 1465456.
49. Screaton GR, Bell MV, Bell JI, Jackson DG. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human and rat. J Biol Chem 1993, 268:12235-12238.
50. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
51. Kollmann K, Heller G, Sexl V. c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard. Oncotarget. 2011, 2:422-427. 3248190, 21789792.
52. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P, Wagner EF. Control of cell cycle progression by c-JUN is p53 dependent. Genes Dev 1999, 13:607-619. 10.1101/gad.13.5.607, 316508, 10072388.
53. Wisdom R, Johnson RS, Moore C. c-JUN regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999, 18:188-197. 10.1093/emboj/18.1.188, 1171114, 9878062.
54. Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon 2006, 4:211-219. 10.1016/S1479-666X(06)80062-4, 16892838.
55. Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol 2007, 608:23-30. 10.1007/978-0-387-74039-3_2, 17993230.
56. Lønning PE. Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol 2003, 4:177-185. 10.1016/S1470-2045(03)01022-2, 12623363.
57. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741. 10.1016/S0006-2952(98)00307-4, 10075079.
58. Suniti M, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 2003, 278:25285-25288. 10.1074/jbc.C300173200, 12738783.
59. Suniti M, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 2005, 280:20310-20315. 10.1074/jbc.M500737200, 15784621.
60. Löffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK, Burger R, Gramatzki M, Blumert C, Bauer K, Cvijic H, Ullmann AK, Stadler PF, Horn F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007, 110:1330-1333. 10.1182/blood-2007-03-081133, 17496199.